WallStSmart
DNLI

Denali Therapeutics Inc

NASDAQ: DNLI · HEALTHCARE · BIOTECHNOLOGY

$18.60
-7.28% today

Updated 2026-04-29

Market cap
$2.95B
P/E ratio
P/S ratio
3,643.65x
EPS (TTM)
$-2.97
Dividend yield
52W range
$13 – $24
Volume
1.7M

Denali Therapeutics Inc (DNLI) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$129.16M$26.68M$335.66M$48.66M$108.46M$330.53M$0.00$0.00
Revenue growth (YoY)-79.3%+1158.2%-85.5%+122.9%+204.7%-100.0%
Cost of revenue$121000.00$1.47M$74.46M$143.18M$193.38M$212.62M$5.61M$7.03M$16.73M$7.79M$11.18M
Gross profit$-121000.00$-1.47M$-74.46M$129.16M$26.68M$335.66M$48.66M$108.46M$330.53M$-7.79M$-11.18M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%
R&D$11.57M$75.70M$74.46M$143.18M$193.38M$212.62M$265.35M$358.73M$423.88M$396.44M$418.78M
SG&A$5.11M$11.73M$15.68M$32.35M$46.48M$60.33M$79.06M$90.47M$103.35M$105.44M$97.10M
Operating income$-16.68M$-87.43M$-90.14M$-46.37M$-213.18M$62.72M$-295.75M$-340.74M$-196.70M$-487.34M$-555.34M
Operating margin-35.9%-799.1%18.7%-607.8%-314.2%-59.5%
EBITDA$-15.06M$-85.96M$-87.06M$-38.96M$-205.19M$71.25M$-287.16M$-330.36M$-179.97M$-492.89M$-497.63M
EBITDA margin-30.2%-769.1%21.2%-590.1%-304.6%-54.4%
EBIT$-15.18M$-87.43M$-90.14M$-46.37M$-213.18M$62.72M$-295.75M$-340.74M$-196.70M$-501.88M$-512.44M
Interest expense$109000.00$0.00$1.96M$1.96M$15.22M$17.77M$13.19M$14.77M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-16.79M$-86.65M$-88.19M$-36.24M$-197.61M$71.14M$-290.58M$-325.99M$-145.22M$-422.77M$-512.54M
Net income growth (YoY)-416.2%-1.8%+58.9%-445.3%+136.0%-508.5%-12.2%+55.5%-191.1%-21.2%
Profit margin-28.1%-740.7%21.2%-597.2%-300.6%-43.9%